Bifidobacterium breve RRJK1316 capable of promoting digestion and application thereof

Abstract

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium breve RRJK1316 capable of promoting digestion and application of the bifidobacterium breve RRJK1316. The bifidobacterium breve is named as bifidobacterium breve (Bifidobacterium breve) RRJK1316, the bifidobacterium breve is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the bifidobacterium breve is GDMCC (Guangdong Microbial Culture Collection Center) No.64764. The strain has relatively strong acid and cholate resistance, can effectively resist the influence of gastric juice, and can still maintain relatively high activity after passing through the digestive tract. The strain has a relatively strong digestion promoting function, and the digestion promoting function is superior to the action concentration of 75.0 mu g / mL of domperidone when the viable cell concentration is 6.00 * 10 < 8 > CFU / mL. Meanwhile, the beta-galactosidase has the function of relieving lactose intolerance, and the enzyme activity of the beta-galactosidase reaches 0.793 U / mL.

Description

Technical Field

[0001] The present invention belongs to the field of microbial technology, and specifically relates to a Bifidobacterium breve RRJK1316 capable of promoting digestion and its application. Background Art

[0002] With the acceleration of the modern life rhythm, changes in dietary structure (such as high-fat, high-sugar, low-fiber diet) and factors such as the abuse of antibiotics, health problems of the digestive system have become increasingly prominent. Specifically, long-term high-fat diet can promote bile acid secretion, change the intestinal pH value, and lead to a decrease in the number of beneficial bacteria such as Bifidobacterium; the use of antibiotics may kill beneficial bacteria in the intestine indiscriminately, causing dysbacteriosis, and then triggering diarrhea, constipation or intestinal inflammation. Common digestive dysfunctions, problems such as indigestion, abdominal distension, constipation, diarrhea and intestinal flora imbalance not only affect the quality of life, but may also cause more serious metabolic diseases (such as obesity, diabetes) and immune system disorders. Therefore, developing safe and effective microecological preparations to improve digestive function has important market value and health significance.

[0003] Currently, commercially available probiotic products mainly contain lactic acid bacteria, Bifidobacterium, etc., but the functions of different strains are different, and the survival rate of some strains in gastric acid and bile is low, making it difficult to effectively colonize the intestine. In addition, the improvement effects of many probiotic products on specific digestive problems are limited. Summary of the Invention

[0004] To solve the above problems, the technical solution of the present invention is as follows: A Bifidobacterium breve capable of promoting digestion, and the Bifidobacterium breve is named Bifidobacterium breve ( Bifidobacterium breve )RRJK1316, which is preserved in the Guangdong Provincial Microbial Culture Collection Center (GDMCC), with the preservation number GDMCC No.64764 and the preservation date of June 17, 2024.

[0005] A bacterial agent, which contains the above-mentioned Bifidobacterium breve capable of promoting digestion.

[0006] A postbiotic, the raw material of which includes the culture, inactivated cells, fermentation products and / or metabolites of the above-mentioned Bifidobacterium breve capable of promoting digestion.

[0007] The above-mentioned postbiotic further includes at least one legally acceptable excipient.

[0008] The above-mentioned culture includes culture broth, culture supernatant, disrupted product, concentrate, sterilized product, gelatinized product or dried product, etc.

[0009] The above-mentioned culture is culture broth or dried product, and the dried product is a powder obtained by spray drying the culture broth.

[0010] Use of the above-mentioned Bifidobacterium breve capable of promoting digestion, the above-mentioned bacterial agent or the above-mentioned postbiotic in the preparation of products that help promote digestion.

[0011] A product that helps to promote digestion, the product comprises the above-mentioned Bifidobacterium breve capable of promoting digestion, the above-mentioned bacterial agent or the above-mentioned postbiotic.

[0012] The above-mentioned product includes medicine or food.

[0013] The above-mentioned products include formula milk, sterilized milk, fermented milk, condensed milk, cream, light cream, anhydrous butter, concentrated milk, compound protein drinks, coffee drinks, plant drinks, flavored drinks, sports drinks, nutrient drinks, energy drinks, electrolyte drinks, whole milk powder, skimmed milk powder, partially skimmed milk powder, formula milk powder, whey powder, cheese, processed cheese, ice cream, slush, popsicles, edible ice, sweet ice or ice cream.

[0014] The above-mentioned product further comprises at least one regulatory acceptable auxiliary material or pharmaceutically acceptable excipient.

[0015] The above-mentioned product, the food includes a nutrient supplement.

[0016] The above-mentioned product, the dosage form of the food includes tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0017] The above-mentioned product, the medicine can be a pharmaceutical composition.

[0018] The Bifidobacterium breve ( Bifidobacterium breve )RRJK1316 has a strong digestive function, 6.00×10 8 The live bacterial concentration of CFU / mL has a better digestion-promoting function than 75.0 μg / mL of domperidone. It also has the function of alleviating lactose intolerance, and the β-galactosidase activity reaches 0.793 U / mL.

[0019] Bifidobacterium breve, named Bifidobacterium breve ( Bifidobacterium breve )RRJK1316 was deposited in the "Guangdong Provincial Microbiological Culture Collection Center" on June 17, 2024, with the deposit number GDMCC No.64764, and the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the colony morphology of Bifidobacterium breve RRJK1316.

[0021] Figure 2It is a typical graph of the fluorescence intensity of the zebrafish intestine, where (a) is the normal control group, (b) is Bifidobacterium breve RRJK1316 at 1500 μg / mL, (c) is the model control group, (d) is Bifidobacterium breve RRJK1316 at 3000 μg / mL, (e) is domperidone at 75.0 μg / mL, and (f) is Bifidobacterium breve RRJK1316 at 6000 μg / mL.

[0022] Bifidobacterium breve( Bifidobacterium breve )RRJK1316, was deposited in the Guangdong Microbial Culture Collection Center (GDMCC) under the deposit number GDMCC No. 64764 on June 17, 2024. Detailed implementation methods

[0023] Example 1 Screening and identification of Bifidobacterium breve RRJK1316 1. Screening of Bifidobacterium breve RRJK1316.

[0024] (1) Isolation.

[0025] Take 0.5 mL of infant fecal sample and add it to 4.5 mL of MRS diluent, and dilute it 10-fold serially to 10 -6 , take an appropriate dilution gradient and spread it on the MRS solid medium petri dish, and culture it in an anaerobic jar at 37 °C for 48 h.

[0026] (2) Purification.

[0027] Pick single colonies with typical characteristics of the target strain, milky white, round, convex, smooth surface, neat edges, and about 3 mm in diameter, and perform streak purification culture on the modified MRS medium until the colony characteristics in the streak petri dish are consistent.

[0028] (3) Microscopic examination.

[0029] In each purified petri dish, pick 2 single colonies for smearing and then perform Gram staining, and observe whether their colors and cell shapes are consistent under the microscope to determine whether the colonies in the petri dish are pure cultures. If the microscopic observation results are consistent, the obtained pure culture (petri dish colonies) is used as a suspected strain, and the corresponding petri dish is numbered for identification; if the microscopic observation results are inconsistent, continue the above operations.

[0030] The improved MRS medium described above: peptone 10 g / L, beef powder 3 g / L, yeast extract powder 4 g / L, dipotassium hydrogen phosphate 2 g / L, citric acid 2 g / L, sodium acetate 5 g / L, glucose 20 g / L, magnesium sulfate heptahydrate 0.58 g / L, manganese sulfate tetrahydrate 0.25 g / L, Tween-80 0.6 g / L, calcium carbonate 10 g / L, neutral red 0.05 g (5 mL of 1% concentration), tomato juice 10 mL / L (v / v), agar powder 20 g / L, adjust the pH to 5.5; sterilize at 115 °C for 30 min.

[0031] 2. Identification of Bifidobacterium breve RRJK1316.

[0032] The purified pure culture was subjected to strain identification, including Gram staining test, catalase test and 16S rDNA full sequence sequencing identification. Finally, the isolated strain was identified as a strain of Bifidobacterium breve, named Bifidobacterium breve ( Bifidobacterium breve )RRJK1316, which was deposited in the "Guangdong Provincial Microbial Culture Collection Center" on June 17, 2024, with the deposit number GDMCC No. 64764.

[0033] The above-mentioned Bifidobacterium breve ( Bifidobacterium breve )RRJK1316 strain is Gram-positive, the cells are polymorphic rods and do not produce spores. The colonies are milky white, round, convex, with a smooth surface and neat edges. Its physicochemical characteristics are: catalase negative, oxidase negative, and it can utilize ribose, lactose, raffinose, sorbitol, mannose, fructose, galactose, sucrose, maltose, trehalose, melibiose, salicin. The 16S rDNA sequence identification result is shown in SEQ ID NO: 1.

[0034] Example 2 Resistance of Bifidobacterium breve RRJK1316 Strain to Adverse Gastrointestinal Environments 1. Acid and bile salt tolerance experiments of Bifidobacterium breve RRJK1316.

[0035] The composition of the medium used in the experiment is as follows: MRS + L medium: yeast peptone 10 g / L, beef powder 3 g / L, yeast extract powder 10 g / L, potassium dihydrogen phosphate 2 g / L, citric acid monohydrate 2 g / L, sodium acetate 5 g / L, anhydrous glucose 20 g / L, magnesium sulfate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 0.6 g / L, tomato juice 10 mL / L, L-cysteine hydrochloride 1 g / L.

[0036] MRS + L solid medium: MRS + L medium, agar powder 12 g / L.

[0037] (1). Acid tolerance test.

[0038] The bacterial solution subcultured three times was inoculated into MRS+L medium with a pH of 3.0 at an inoculation amount of 10%. Samples were taken after anaerobic culture at 39±0.5°C for 3 h at 0 h, and then serially diluted 10-fold with sterilized normal saline. 1000 μL of the bacterial solution at an appropriate dilution was taken for viable count operation, with 2 replicates for each dilution. After anaerobic culture at 39±0.5°C on MRS+L solid medium for 48 - 72 h, the count was performed.

[0039] Acid tolerance test data indicators: viable count measured at 3 h after culture (denoted as N′); viable count measured at 0 h after culture (denoted as N0). The logarithmic ratio formula for acid-tolerant viable count is as follows: Acid tolerance survival rate (%) of the tested strain = lg cfu N′ / lg cfu N0 × 100%; Table 1 Acid tolerance test data of Bifidobacterium breve RRJK1316

[0040] As can be seen from the above table, the survival rate of Bifidobacterium breve RRJK1316 strain still reached 96.45% after 3 hours at pH 3.0, indicating that the strain can still maintain a high activity after being inhibited by gastric acid, thus exerting its probiotic effect.

[0041] (2) Bile salt tolerance test.

[0042] The bacterial solution subcultured three times was inoculated into 10 mL of MRS+L liquid medium containing 0.3% and 0.5% bile salt concentrations at an inoculation amount of 10% respectively. Samples were taken after anaerobic culture in an anaerobic jar at 39±0.5°C for 4 h at 0 h, and then serially diluted 10-fold with sterilized normal saline. 1 mL of the bacterial solution at an appropriate dilution was taken for viable count operation, with 2 replicates for each dilution. After anaerobic culture in an anaerobic jar at 39±0.5°C on MRS+L solid medium for 48 - 72 h, the count was performed.

[0043] Bile salt tolerance test data indicators: viable count measured at 4 h after culture (denoted as N′); viable count measured at 0 h after culture (denoted as N0). The logarithmic ratio formula for acid-tolerant viable count is as follows: Acid tolerance survival rate (%) of the tested strain = lg cfu N′ / lg cfu N0 × 100%; Table 2 Bile salt tolerance test data of Bifidobacterium breve RRJK1316

[0044] As can be seen from Table 2, the survival rate of Bifidobacterium breve RRJK1316 strain increased with the increase of bile salt concentration, and the survival rate could reach 100% under the treatment of 0.5% bile salt concentration.

[0045] Simulated gastric juice test of Bifidobacterium breve RRJK1316

[0046] The bacterial liquid after three passages was shaken well, and 10 mL of the bacterial suspension was centrifuged (5000 g, 10 min, 4 °C) to obtain bacterial mud. The bacterial mud was washed twice with PBS buffer, and the obtained bacterial mud was resuspended in 10 mL of simulated gastric juice. After anaerobic digestion at 39 ± 0.5 °C for 3 h, samples were taken, serially diluted 10-fold with sterilized normal saline, 1 mL of the bacterial liquid at an appropriate dilution was taken for mixed bacterial counting operation, with 2 replicates for each dilution, and the count was performed after culturing in an anaerobic jar at 39 ± 0.5 °C for 48 - 72 h.

[0047] Data indicators for simulated gastrointestinal fluid tests: Data indicators for simulated gastric juice tests: The viable count of the tested strain after three generations of activation in the third-generation culture solution (denoted as N); the viable count measured by sampling and counting at 3 h (denoted as N”). Survival rate (%) of the tested strain in the simulated gastric juice test = lgcfu N” / lgcfu N × 100%.

[0048] Table 3 Data table of simulated gastric juice test of Bifidobacterium breve RRJK1316

[0049] As can be seen from Table 3, the Bifidobacterium breve RRJK1316 strain has strong survival ability in simulated gastric juice. After 3 h of treatment, the survival rate is as high as 100.0%, and it still maintains high activity after staying in the stomach for a long time.

[0050] In summary, it shows that this strain has strong acid and bile salt tolerance, and can effectively resist the influence of gastric juice, so that it can still maintain high activity after passing through the digestive tract.

[0051] Example 3 Promoting digestion efficacy test of Bifidobacterium breve RRJK1316 1. Determination of the maximum test concentration (MTC).

[0052] Wild-type AB strain zebrafish at 3 days post-fertilization (3 dpf) were randomly selected in a culture dish. Except for the normal control group, the other experimental groups were given TNBS in water to establish a zebrafish indigestion model. After treatment at 28 °C for 2 days, TNBS was removed, and the zebrafish were randomly assigned to a 6-well plate, with 30 zebrafish in each well (experimental group). The samples were given in water (concentrations are shown in Table 4), and at the same time, a normal control group and a model control group were set up, with a volume of 3 mL in each well. After treatment at 28 °C until 7 dpf, the MTC of the samples for the model zebrafish was determined.

[0053] 2. Evaluation of promoting digestion efficacy.

[0054] Randomly select 3 dpf wild-type AB strain zebrafish in a culture dish. Except for the normal control group, the other experimental groups were given TNBS in water to establish a zebrafish indigestion model. After treatment at 28 °C for 2 days, remove TNBS and give Nile red in water as a fluorescent indicator for intestinal contents. After feeding, randomly distribute the zebrafish into 6-well plates, with 30 zebrafish in each well (experimental group). Administer the sample in water (concentrations are shown in Table 5), with the positive control domperidone at a concentration of 75.0 μg / mL. At the same time, set up a normal control group and a model control group, and the volume of each well is 3 mL. Treat at 28 °C until 7 dpf, randomly select 10 zebrafish from each group to take pictures and save the pictures under a fluorescence microscope, use NIS-Elements D 3.20 advanced image processing software to analyze and collect data, analyze the intestinal fluorescence intensity of zebrafish, and evaluate the efficacy of the sample in improving indigestion based on the statistical analysis results of this index. The statistical treatment results are expressed as mean ± SE. Use SPSS 26.0 software for statistical analysis, p < 0.05 indicates that the difference is statistically significant.

[0055] 3. Detection results.

[0056] (1). MTC.

[0057] Under the conditions of this experiment, the MTC of Bifidobacterium breve RRJK1316 for promoting digestion in zebrafish was 6000 μg / mL. See Table 4 for details.

[0058] Table 4 Results of the concentration exploration experiment for the digestion-promoting effect of the sample (n = 30)

[0059] (2). Evaluation of the digestion-promoting effect.

[0060] Under the conditions of this experiment, Bifidobacterium breve RRJK1316 has a digestion-promoting effect, specifically manifested as reducing the intestinal fluorescence intensity of zebrafish. See Table 5 and Figure 2 .. The fluorescence intensity of the Bifidobacterium breve RRJK1316 group was significantly lower than that of the model control group. When the concentration of Bifidobacterium breve RRJK1316 was 6000 μg / mL, that is, 6.00 × 10 8 CFU / mL of live bacteria, the intestinal fluorescence intensity of zebrafish was lower than that of domperidone, indicating that the digestion-promoting function at this concentration was better than the action concentration of domperidone at 75.0 μg / mL.

[0061] Table 5 Results of the evaluation experiment for the digestion-promoting effect of the sample (n = 10)

[0062] Compared with the model control group, **p < 0.01, *** p < 0.001。

[0063] Example 4: Efficacy test of Bifidobacterium breve RRJK1316 in alleviating lactose intolerance Experimental principle and test strains.

[0064] O-nitrophenyl β-D-galactopyranoside (ONPG) is a colorless compound soluble in water and can be used as a substrate for β-galactosidase. Under the catalytic action of the enzyme, the glycosidic bond is broken, producing o-nitrophenol (ONP) and β-D-galactopyranose. The product ONP is a yellow substance. As the substrate decomposes, the color of the solution gradually deepens and has a maximum absorption peak at 420 nm. Therefore, the ONP yield can be calculated by measuring its absorbance.

[0065] Table 6 Information of Bifidobacterium breve RRJK1316 and control strains

[0066] 2. Culture medium and culture conditions (1) Formula of solid medium for Bifidobacterium breve

[0067] Yeast peptone 10 g / L, beef powder 3 g / L, yeast extract powder 10 g / L, potassium dihydrogen phosphate 2 g / L, citric acid monohydrate 2 g / L, sodium acetate 5 g / L, anhydrous glucose 20 g / L, magnesium sulfate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 0.6 g / L, tomato juice 10 mL / L, L-cysteine hydrochloride 1 g / L, pH adjusted to 6.5 ± 0.02. After dispensing, add agar powder 10 g / L and sterilize at 115 °C for 30 min.

[0068] (2) Formula of Bifidobacterium breve - lac medium (liquid)

[0069] Yeast peptone 10 g / L, beef powder 3 g / L, yeast extract powder 10 g / L, potassium dihydrogen phosphate 2 g / L, citric acid monohydrate 2 g / L, sodium acetate 5 g / L, lactose 20 g / L, magnesium sulfate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 0.6 g / L, tomato juice 10 mL / L, L-cysteine hydrochloride 1 g / L, pH adjusted to 6.5 ± 0.02.

[0070] 3. Reagents for experiments

[0071] (1) Reaction buffer

[0072] Weigh 8.8 g of potassium dihydrogen phosphate (KH2PO4), 8.0 g of dipotassium hydrogen phosphate trihydrate (K2HPO4·3H2O), 0.25 g of magnesium sulfate heptahydrate (MgSO4·7H2O) and 18.6 mg of EDTA disodium dihydrate (C 10 H 14 N2Na2O8·2H2O), dissolve them in 900 mL of water, transfer to a 1000 mL volumetric flask, make up the volume with water and shake well. The pH value of the buffer solution should be between 6.50 ± 0.05.

[0073] (2) o-Nitrophenyl-β-D-galactopyranoside (ONPG) substrate solution.

[0074] Dissolve 250.0 mg of o-nitrophenyl-β-D-galactopyranoside (ο-nitrophenyl-β-D-galactopyranoside, ONPG) in approximately 80 mL of reaction buffer, then transfer to a 100 mL volumetric flask, make up the volume with reaction buffer and shake well. It should be prepared at the earliest 2 h before use.

[0075] (3) Sodium carbonate solution.

[0076] Dissolve 50 g of sodium carbonate (Na2CO3) and 37.2 g of EDTA disodium dihydrate in approximately 900 mL of water and make up the volume to 1000 mL.

[0077] 4. Operating procedures.

[0078] (1) Preparation of the standard curve.

[0079] Weigh 0.1390 g of o-nitrophenol (ONP) into a small beaker, dissolve it with 10 mL of 96% ethanol, then transfer the solution into a 1 L volumetric flask, make up the volume with water and shake well; Using a pipette, transfer 2 mL, 4 mL, 6 mL, 8 mL, 10 mL, 12 mL, 14 mL of the solution from these solutions into different 100 mL volumetric flasks respectively, add 25 mL of sodium carbonate solution, make up the volume with buffer solution and shake well to prepare ONP with concentrations of 0.02 mmol / L, 0.04 mmol / L, 0.06 mmol / L, 0.08 mmol / L, 0.10 mmol / L, 0.12 mmol / L and 0.14 mmol / L. Use sterile water as the blank; Taking the amount of substance of o-nitrophenol as the abscissa and the absorbance ΔOD 420 of the dilution as the ordinate, plot the standard curve and obtain the regression equation.

[0080] (2) Preparation of the test strains.

[0081] (a) Primary culture: Take out the strain cryopreservation tube stored at -80°C, thaw it by hand, mix well, take 1 loop of the bacterial liquid and streak it on a solid plate of Bifidobacterium breve, and culture it anaerobically at 39 ± 0.5°C for 48 - 72 h; (b) Secondary culture: Pick a single colony into 5 mL of Bifidobacterium breve - lac liquid medium, culture it at 39°C for 20 h ± 0.5, and culture it with aluminum foil covered; (c) Tertiary culture: Inoculate 5 mL of the bacterial liquid into 100 mL of Bifidobacterium breve - lac liquid medium, culture it at 39°C for 16 - 20 h, and culture it with aluminum foil covered.

[0082] (3) Determination experiment of β - galactosidase activity (ONPG method).

[0083] Centrifuge 15 mL of the cultured fermentation broth at 10000 r / min for 5 min at 4°C. Collect the bacterial sludge and wash it twice with an equal volume of 0.05 mol / L phosphate buffer (pH 6.8). Resuspend the bacterial cells in 3 mL of the above - mentioned phosphate buffer and perform ultrasonic disruption. The disruption conditions are: ultrasonic power 200 W, working time / interval time 1 s / 9 s, 60 times, 4°C. Centrifuge at 10000 r / min for 20 min at 4°C and take the supernatant to obtain the crude enzyme solution. Dilute the crude enzyme solution appropriately, then take 200 μL of the crude enzyme solution and pre - heat it in a water bath at 30°C for 5 min, add 1 mL of ONPG solution that has also been pre - heated at 30°C for 5 min, shake well, incubate in a water bath at 30°C for 10 min, and then immediately add 400 μL of sodium carbonate solution to terminate the reaction. Measure the OD value at 420 nm within 30 min.

[0084] Preparation of the blank sample: Reverse the order of adding the ONPG substrate and sodium carbonate solution, and the remaining steps are the same as the sample treatment method.

[0085] One enzyme activity unit (E) is defined as: the amount of enzyme required to hydrolyze and release 1 μmoL of ONP per minute at 30°C. Calculate the enzyme activity E (U / mL) according to the following formula.

[0086] 4. Test results.

[0087] Calculation formula for enzyme activity of T:

[0088] In the formula: E is the enzyme activity in the fermentation broth, U / mL; f is the dilution factor of the measured enzyme solution; V is the total volume of the reaction system, 1.6 mL; K is the slope of the standard curve, 3.1625; t is the reaction time, 10 min; V1 is the volume of the enzyme solution, 0.2 mL.

[0089] Table 7 Data of the test for relieving lactose intolerance of RRJK1316 and the control strain

[0090] As can be seen from the test data in Table 7, the β-galactosidase activity of Bifidobacterium breve RRJK1316 reached 0.793 U / mL, and the data had obvious advantages compared with the control strain, indicating that Bifidobacterium breve RRJK1316 had a strong function of alleviating lactose intolerance.

[0091] Example 5: Cultivation method of Bifidobacterium breve RRJK1316 Transfer the bacteria in the cryopreservation tube to 10 mL of basal medium according to an inoculation amount of 10%, and anaerobically culture statically at 37.0 ± 0.5 °C for 17.0 ± 0.5 h to obtain a bacterial suspension; transfer the bacterial suspension to 100 mL of basal medium according to an inoculation amount of 5%, and anaerobically culture statically at 37.0 ± 0.5 °C for 17.0 ± 0.5 h; inoculate the bacterial suspension into 300 mL of optimized medium, and anaerobically culture statically at 37.0 ± 0.5 °C for 17.0 ± 0.5 h; measure the viable count of the bacterial suspension to be 5.0×10 9 CFU / mL or more.

[0092] The composition of the basal medium is as follows: Anhydrous glucose 30 g / L, yeast extract powder 10 g / L, yeast peptone 15 g / L, citric acid 2 g / L, sodium acetate 5 g / L, potassium dihydrogen phosphate 2 g / L, magnesium sulfate 0.5 g / L, manganese sulfate 0.01 g / L, Tween-80 0.6 g / L, soy peptone 5 g / L, adjust the pH to 7.20. The liquid loading volume is 80%.

[0093] The composition of the optimized medium is as follows: Anhydrous glucose 30 g / L, yeast extract powder 15 g / L, yeast peptone 15 g / L, citric acid 2 g / L, sodium acetate 5 g / L, potassium dihydrogen phosphate 2 g / L, magnesium sulfate 0.5 g / L, manganese sulfate 0.01 g / L, Tween-80 0.6 g / L, soy peptone 10 g / L, adjust the pH to 7.20. The liquid loading volume is 80%.

Claims

1. A Bifidobacterium breve capable of promoting digestion, characterized in that, The Bifidobacterium breve described above is named Bifidobacterium breve ( Bifidobacterium breve ) RRJK1316, which is deposited in the Guangdong Microbial Culture Collection Center (GDMCC) with the deposit number of GDMCC No. 64764.

2. A bacterial agent, characterized in that, The bacterial agent contains the Bifidobacterium breve capable of promoting digestion described in claim 1.

3. A postbiotic, characterized in that, The raw materials of the postbiotic include the culture, inactivated cells, fermentation products, and / or metabolites of the Bifidobacterium breve capable of promoting digestion described in claim 1.

4. Use of the Bifidobacterium breve capable of promoting digestion described in claim 1, or the bacterial agent described in claim 2, or the postbiotic described in claim 3 in the preparation of a product helpful for promoting digestion.

5. A product that helps promote digestion, characterized in that, The product contains the Bifidobacterium breve capable of promoting digestion described in claim 1, or the bacterial agent described in claim 2, or the postbiotic described in claim 3.

6. The product according to claim 5, wherein, The product includes a drug or food.

7. The product according to claim 6, characterized in that, The product further contains at least one legally usable auxiliary material or pharmaceutically acceptable excipient.

8. The product according to claim 6, wherein The food includes a nutrient supplement.

9. The product according to claim 8, wherein, The dosage form of the food includes, but is not limited to, tablets, capsules, soft capsules, granules, pills, gummy candies, powders, oral liquids, or drops.

Images